Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) just unveiled an update.
Shanghai Pharmaceuticals Holding Co., Ltd. has released additional information regarding its 2024 annual report, specifically addressing connected transactions and its Share Option Scheme. The company clarified details about ongoing connected transactions with Yunnan Baiyao Group Co., Ltd., Wing Fat Printing Limited, and property leasing agreements with Shanghai Pharma Group. Additionally, the company reported that there were no options available for grant under its Share Option Scheme as of the reporting period, with a total of 680,000 A Shares available for issue, representing a small fraction of the company’s total shares.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a leading company in the pharmaceutical industry based in China. It is involved in the manufacturing and distribution of pharmaceutical products and medical devices, focusing on both domestic and international markets.
Average Trading Volume: 4,060,084
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$76.68B
Find detailed analytics on 2607 stock on TipRanks’ Stock Analysis page.